ardis final
TRANSCRIPT
Alex Etlin, PhD Vickie Zhang, PhD(c) Brandon Lujan, MD Luke Lee, MBA
Advanced Retinal Diagnostic Imaging Services
Total Interviews: 101
Total Available Market$12 billion
Target Market$120 million
How big is the opportunity?
Asymptomatic individuals over age 60
Customer Segments
Asymptomatic individuals (> 60)
Patients with mild AMD
Clinicians
We interviewed > 30 asymptomatic older adults & AMD patients
• Asymptomatic adults don’t care to be imaged
• Most AMD patients would like to be monitored more frequently
What do clinicians say?
Clinical evidence showing frequent monitoring results in better patient outcomes.
Clinicians don’t think they should pay for our service.
LILLIE MOSADDEGH MD
To get and keep patients,
“you have to provide easy access and financial support so patients don’t have to pay.”
Then patients would want to show up
We learned:Customer segments What do they want?
Asymptomatic individuals
Patients Would like to be monitored frequentlyPrefer easy access to careSome are willing to pay
Clinicians Want to see clinical evidenceDo not want to pay
Who should be our payers?Insurance companies? Pharma companies?
What do insurance companies say?
• Clinical evidence that frequent monitoring leads to better patient outcomes
• Frequent monitoring would reduce overall healthcare costs!
Validation: Early detection of disease progression => decrease cost of treatments
CLINICAL TRIAL
Industry: Overwhelmed by Data
“We Need insight from
existing clinical data”
To better design what is coming next:
Who to include?What endpoints?
Where do we go from here?
1. Already submitted three analysis proposals
2. How can we build value using other’s data?
3. Perform our own trial and protect insights